Encouraged by the efficient tumor homing and ICD-induction capacity of Oxa(IV)@ZnPc@M, we next evaluated whether the antitumor immunity triggered by chemo-photodynamic therapy of Oxa(IV)@ZnPc@M could be harnessed to potentiate checkpoint blockade therapy (e.g. anti-PD-L1) to enhance antitumor and anti-metastasis efficacy. This evidence concerns the gene CD274 and neoplasm.